BCL2 and acute myeloid leukemia: Patients with newly diagnosed AML who are predicted to have poor responsiveness toward intensive 7+3 chemotherapy could be prescribed alternative therapies such as a hypomethylating agent,70,71 Bcl-2 inhibitor,62 and/or FLT3 kinase inhibitor.72